China Pharma Price To Sales Ratio Over Time
| CPHI Stock | USD 0.22 0.02 8.33% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out China Pharma Performance and China Pharma Correlation. China |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share | Quarterly Revenue Growth (0.16) | Return On Assets | Return On Equity |
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Price To Sales Ratio Analysis
Compare China Pharma Holdings and related stocks such as Universe Pharmaceuticals, Sonoma Pharmaceuticals, and Acorda Therapeutics Price To Sales Ratio Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UPC | 12.6 K | 12.6 K | 12.6 K | 12.6 K | 12.6 K | 12.6 K | 12.6 K | 12.6 K | 1.9 K | 2 K | 672 | 184 | 63.9533 | 63.9533 | 73.55 | 69.87 |
| SNOA | 59.199 | 5.7164 | 2.1709 | 3.7965 | 1.1709 | 0.4162 | 4.7228 | 2.0014 | 0.8066 | 0.7644 | 1.5922 | 1.6849 | 0.4994 | 0.2184 | 0.25 | 0.24 |
| AKAN | 588.7 K | 588.7 K | 588.7 K | 588.7 K | 588.7 K | 588.7 K | 588.7 K | 588.7 K | 588.7 K | 588.7 K | 588.7 K | 29.3 K | 7.8803 | 143 | 165 | 157 |
| SXTC | 154 | 154 | 154 | 154 | 154 | 154 | 154 | 154 | 154 | 21.4637 | 44.3396 | 17.9004 | 7.6801 | 5.9732 | 6.87 | 6.53 |
| PTPI | 0.284 | 0.284 | 0.284 | 0.284 | 0.284 | 0.284 | 0.284 | 0.284 | 0.284 | 0.4372 | 4.4682 | 4.6424 | 0.805 | 0.527 | 0.0062 | 0.0059 |
| BFRI | 2 K | 2 K | 2 K | 2 K | 2 K | 2 K | 2 K | 2 K | 2 K | 2 K | 2.7 K | 5.3 K | 676 | 126 | 161 | 153 |
| SHPH | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| LFCR | 1.3353 | 1.3353 | 1.3353 | 1.3353 | 1.3353 | 1.3353 | 1.3353 | 1.3353 | 1.3353 | 1.3353 | 1.3353 | 1.3353 | 1.3353 | 1.3353 | 0.2143 | 0.2 |
China Pharma Holdings and related stocks such as Universe Pharmaceuticals, Sonoma Pharmaceuticals, and Acorda Therapeutics Price To Sales Ratio description
Price to Sales Ratio is figured by comparing China Pharma Holdings stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on China Pharma sales, a figure that is much harder to manipulate than other China Pharma Holdings multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.My Equities
My Current Equities and Potential Positions
| China Pharma Holdings | CPHI |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | China |
| Exchange | NYSE MKT Exchange |
USD 0.22
Check out China Pharma Performance and China Pharma Correlation. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
China Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.